Case study

A clearer strategy for foreign-generated data

Targeted EU and UK scientific advice helped a sponsor understand how its existing pivotal data could inform a registration strategy.

Anonymised engagement drawn from our team’s experience.

Challenge

The key uncertainty was whether existing pivotal evidence could support registration in the EU and UK.

A client’s pivotal data package had been generated outside the EU and UK, leaving an open question about its acceptability for registration in those markets. The client’s initial preference was to request centralised scientific advice from the European Medicines Agency (EMA).

Solution

The team defined the question the client needed answered before choosing the advice pathway. This kept the interactions focused on data acceptability.

  1. Reframe the regulatory question

    The team assessed what needed to be established about the foreign-generated data before committing to centralised scientific advice.

  2. Compare EU and UK perspectives

    Parallel national interactions with an EU reference state and the MHRA explored their views on the same pivotal data package.

  3. Inform the submission strategy

    The interactions explored any differences in expectations before the client committed to a filing strategy based on its existing evidence.

Results

Outcome

Regulatory strategy clarified

The advice clarified the regulatory position on the data package and supported an informed submission strategy. The engagement also strengthened the client team’s ability to assess future foreign-data cases.

Your case

Planning how to use your existing evidence?

Discuss the questions to resolve before choosing a scientific advice or submission pathway.

We aim to reply within two working days. Language support is agreed for each engagement.